Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Director | January 29, 2019 | January 31, 2019 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CymaBay Therapeutics, Inc.
Report date January 29, 2019 · Filed January 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28 | Direct | 27,705 |
Reported balance
After 2019-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-29 · Grant · Acquired 27,705 · Balance 27,705 F1: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019.
Summit Therapeutics Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 35,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 35,000 · Balance 35,000 F2: Not applicable. F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 7,180 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 7,180 · Balance 7,180 F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $62,900. F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $62,900.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 18:55 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 7,180 | $8.76 Strike: $17.52 | $62,896.80 |
DisclosureSEC source: 0001507567-26-000003 · wk-form4_1767743714.xml · derivative · entry 2 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,180 Underlying: Common Stock · 7,180 shares Expires 2036-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $62,900. F3 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 18:55 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $17.52 | Not disclosed |
DisclosureSEC source: 0001507567-26-000003 · wk-form4_1767743714.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:57 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 6,855 | $9.18 Strike: $18.35 | $62,928.90 |
DisclosureSEC source: 0001599298-25-000022 · wk-form4_1736207824.xml · derivative · entry 2 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,855 Underlying: Common Stock · 6,855 shares Expires 2035-01-02 F4 · price: The option was issued to the reporting person pursuant to the Director Retainer Option Election Plan of issuer in lieu of retainer fees of $62,900. F3 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:57 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $18.35 | Not disclosed |
DisclosureSEC source: 0001599298-25-000022 · wk-form4_1736207824.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:27 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 47,651 | $1.32 Strike: $2.64 | $62,899.32 |
DisclosureSEC source: 0001599298-24-000014 · wk-form4_1704403621.xml · derivative · entry 2 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,651 Underlying: Common Stock · 47,651 shares Expires 2034-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $62,900. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:27 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.64 | Not disclosed |
DisclosureSEC source: 0001599298-24-000014 · wk-form4_1704403621.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:21 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 32,700 | $1.67 Strike: $5.00 | $54,609.00 |
DisclosureSEC source: 0001507567-23-000003 · wf-form4_167295366118350.xml · derivative · entry 2 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,700 Underlying: Common Stock · 32,700 shares Expires 2033-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $54,500. F3 · derivative.exercise_date: The option was issued on January 3, 2023. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:21 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001507567-23-000003 · wf-form4_167295366118350.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| September 28, 2022 Filed Oct 3, 2022 16:50 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 6,250 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001839882-22-022703 · booth-form4_093022.xml · derivative · entry 2 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 6,250 shares Expires 2032-09-28 F3 · price: Not applicable. F2 · derivative.exercise_date: The option was granted on September 28, 2022 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days the Reporting Person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2022. Read SEC document |
| September 28, 2022 Filed Oct 3, 2022 16:50 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001839882-22-022703 · booth-form4_093022.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-09-28 F3 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on September 28, 2022. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on September 28, 2023. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:19 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 27,705 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001333277-19-000019 · edgar.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,705 Underlying: Common Stock · 27,705 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000019 · edgar.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 09:30 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-17-053895 · doc4.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-09-21 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 14:42 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001042074-17-000014 · primary_doc.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| January 19, 2017 Filed Jan 23, 2017 17:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001179110-17-001182 · edgar.xml · derivative · entry 1 Booth Robert F. · CIK 0001507567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The option vests in three annual installments from the vesting start date of December 6, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.